文摘
The molecular modification and synthesis of compounds is vital to discovering drugs with desirable pharmacological and toxicity profiles. In response to pyrazole compounds' antipyretic, analgesic, and anti-inflammatory effects, this study sought to evaluate the analgesic, anti-inflammatory, and vasorelaxant effects, as well as the mechanisms of action, of a new pyrazole derivative, 5-[1-(4-fluorophenyl)-1m>Hm>-pyrazol-4-yl]-2m>Hm>-tetrazole. During the acetic acid-induced abdominal writhing test, treatments with 5-[1-(4-fluorophenyl)-1m>Hm>-pyrazol-4-yl]-2m>Hm>-tetrazole reduced abdominal writhing, while during the formalin test, 5-[1-(4-fluorophenyl)-1m>Hm>-pyrazol-4-yl]-2m>Hm>-tetrazole reduced licking times in response to both neurogenic pain and inflammatory pain, all without demonstrating any antinociceptive effects, as revealed during the tail flick test. 5-[1-(4-fluorophenyl)-1m>Hm>-pyrazol-4-yl]-2m>Hm>-tetrazole also reduced carrageenan-induced paw edema and cell migration during the carrageenan-induced pleurisy test. As demonstrated by the model of the isolated organ, 5-[1-(4-fluorophenyl)-1m>Hm>-pyrazol-4-yl]-2m>Hm>-tetrazole exhibits a vasorelaxant effect attenuated by Nω-nitro-mallCaps">l-arginine methyl ester, 1H-[1,2,4]oxadiazolo[4,3-alpha]quinoxalin-1-one, tetraethylammonium or glibenclamide. 5-[1-(4-fluorophenyl)-1m>Hm>-pyrazol-4-yl]-2m>Hm>-tetrazole also blocked CaCl2-induced contraction in a dose-dependent manner. Suggesting a safe toxicity profile, 5-[1-(4-fluorophenyl)-1m>Hm>-pyrazol-4-yl]-2m>Hm>-tetrazole reduced the viability of 3T3 cells at higher concentrations and was orally tolerated, despite signs of toxicity in doses of 2000 mg/kg. Lastly, the compounds' analgesic activity might be attributed to the involvement of the NO/cGMP pathway and K+ channels observed in the vasorelaxant effect.